Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy

OBJECTIVE: To assess the dose-ranging efficacy and safety of LX4211, a dual inhibitor of sodium–glucose cotransporter (SGLT) 1 and SGLT2, in type 2 diabetes. RESEARCH DESIGN AND METHODS: Type 2 diabetic patients inadequately controlled on metformin were randomly assigned to 75 mg once daily, 200 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Cefalu, William T., Lapuerta, Pablo, Zambrowicz, Brian, Ogbaa, Ike, Banks, Phillip, Sands, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2015
Materias:
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131876/
https://www.ncbi.nlm.nih.gov/pubmed/25216510
http://dx.doi.org/10.2337/dc14-0890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131876/
https://www.ncbi.nlm.nih.gov/pubmed/25216510
http://dx.doi.org/10.2337/dc14-0890

Ejemplares similares